This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haraf, D. J. Articles by Vokes, E. E. Search for Related Content PubMed PubMed Citation Articles by Haraf, D. J. Articles by Vokes, E. E. Social Bookmarking                            What's this?

Radiation Therapy With Concomitant Hydroxyurea and Fluorouracil in Stage II and III Head and Neck Cancer

From the Department of Radiation and Cellular Oncology, Section of Otolaryngology/Head and Neck Surgery, and Section of Hematology/Oncology, University of Chicago; Section of Medical Oncology, Department of Preventative Medicine, Section of Radiation Oncology, and Department of Otolaryngology/Head and Neck Surgery, Northwestern University; and Department of Otolaryngology/Head and Neck Surgery, University of Illinois, Chicago, IL.

Address reprint requests to Daniel J. Haraf, MD, Department of Radiation Oncology, 5758 S. Maryland, MC 9006, Chicago, IL 60637; email dharaf{at}mcis.bsd.uchicago.edu

PURPOSE: In 1986, a multi-institutional phase II trial was begun to study the use of chemotherapy with concomitant radiation in patients with stage II and III head and neck cancer. End points were overall survival, progression-free survival, local/regional control, and toxicity in the setting of organ preservation with concomitant treatment.

METHODS: Eligible patients with stage II or III disease received chemotherapy and radiation on a 2-week cycle. Chemotherapy consisted of continuous infusion fluorouracil (5-FU) at 800 mg/m²/d for 5 consecutive days (days 1 to 5) and hydroxyurea (HU) at 1 g orally every 12 hours for 13 doses starting the evening before the start of irradiation. Radiation therapy was given as single 1.8- to 2.0-Gy fractions for 5 consecutive days (days 1 to 5) with chemotherapy. Each 5 days of treatment was followed by a 9-day break (days 6 to 14), during which no additional treatment was given. Treatment cycles were repeated until the completion of the planned radiation dose (six to eight cycles).

RESULTS: Between 1989 and 1996, 60 patients were enrolled. All patients were eligible for analysis, with a median follow-up of 52 months for surviving patients and 42 months for all patients. Grade 3 to 4 mucositis occurred in 57% of patients. The 5 year-actuarial overall survival, progression-free survival, and local/regional control were 65%, 82%, and 86%, respectively. Eight patients developed local and/or regional recurrence after treatment. Surgical salvage was possible in three of these patients. Thus, the ultimate 5-year local/regional control was 91%.

CONCLUSION: Concomitant radiation and chemotherapy with 5-FU and HU is an effective regimen in patients with stage II and III head and neck cancer. Progression-free survival and local/regional control appear to be superior to expected rates in patients treated with surgery and radiation. Further testing of this regimen in a phase III setting is indicated.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. E.W. Cohen, D. J. Haraf, M. A. List, M. Kocherginsky, B. B. Mittal, F. Rosen, B. Brockstein, R. Williams, M. E. Witt, K. M. Stenson, et al. High Survival and Organ Function Rates After Primary Chemoradiotherapy for Intermediate-Stage Squamous Cell Carcinoma of the Head and Neck Treated in a Multicenter Phase II Trial J. Clin. Oncol., July 20, 2006; 24(21): 3438 - 3444. [Abstract] [Full Text] [PDF]

				A.S. Garden, J. Harris, E.E. Vokes, A.A. Forastiere, J.A. Ridge, C. Jones, E.M. Horwitz, B.S. Glisson, L. Nabell, J.S. Cooper, et al. Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck J. Clin. Oncol., July 15, 2004; 22(14): 2856 - 2864. [Abstract] [Full Text] [PDF]

				A. Argiris, D. J. Haraf, M. S. Kies, and E. E. Vokes Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil- and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure Oncologist, August 1, 2003; 8(4): 350 - 360. [Abstract] [Full Text] [PDF]

				R. Hitt, L. Paz-Ares, A. Brandariz, D. Castellano, C. Pena, J. M. Millan, F. Calvo, D. Ortiz de Urbina, E. Lopez, J. J. Alvarez-Vicent, et al. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial Ann. Onc., October 1, 2002; 13(10): 1665 - 1673. [Abstract] [Full Text] [PDF]

				E. E. Vokes, M. S. Kies, D. J. Haraf, K. Stenson, M. List, R. Humerickhouse, M. E. Dolan, H. Pelzer, L. Sulzen, M. E. Witt, et al. Concomitant Chemoradiotherapy as Primary Therapy for Locoregionally Advanced Head and Neck Cancer J. Clin. Oncol., April 1, 2000; 18(8): 1652 - 1661. [Abstract] [Full Text] [PDF]